Fermion-Header

Fermion-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Novo Nordisk

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SupplySide West 2021

Participation Not Confirmed

Update your Virtual Booth

Novo Nordisk’s Ziltivekimab Hits Primary Endpoint in CKD Trial

Lead Product(s): Ziltivekimab

Therapeutic Area: Nephrology Product Name: COR-001

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2021

Details:

The RESCUE trial assessed the effect of once-monthly subcutaneous ziltivekimab on biomarkers of inflammation in patients with advanced CKD and elevated hsCRP.